Oya Levendoglu-Tugal, MD

  • Professor, Clinical Pediatrics
    Director of Thrombosis and Hemostasis Program
    Director, Histiocytic Disorders
    Medical Director, Ambulatory Pediatric Hematology/Oncology and Stem Cell Transplantation


Undergraduate: Hacettepe University Faculty of Medicine, School of Basic Sciences
Graduate: Hacettepe University Faculty of Medicine, Ankara Turkey.
Residency: Hacettepe Medical Center, Hacettepe Children’s Hospital in Ankara, Turkey (1974-1978)
Fellowship: Immunology at Hacettepe Medical Center, Hacettepe Children’s Hospital Ankara Turkey (1977-1978)


Board Certifications

Turkish Board of Pediatrics
American Board of Pediatrics
American Sub-Board of Pediatric Hematology-Oncology


Areas of Interest and Expertise

Childhood cancers including leukemia, lymphoma, neuroblastoma, solid tumors, brain tumors, histiocytic disorders, platelet disorders, hemoglobinopathies, bleeding, and thrombosis.

In addition to her vast experience and active involvement in the treatment of pediatric oncology patients, Dr. Tugal’s main focus in recent years is in pediatric bleeding disorders and thrombosis. She is conducting a clinical research in the treatment of venous thrombosis in children with a novel oral anticoagulant. Histiocytic disorders in children is one of her strong interests.


Office Locations:




Sujith Sheth, Gerald Soff, Beau Mitchell, David Green, Shipra Kaicjer, Fernando Fireman, Oya Tugal, Ludovico Guarini, Patricia Giardina, and  Louis Aledort. Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report. Expert Review of Hematology. February 2012, Vol 5, No. 1. Pages 47-50.

A. Valentino, C.E. Walsh, M.T. Reding, G.A.Young, O. Levendoglu-Tugal and D. L. Cooper. Haemophilia. (2012) 1-7. Patient and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the dosing observational study in haemophilia (DOSE).

International Society and Pharmacoeconomics and Outcomes Reach. 15th Annual International Meeting. May 15-19, 2010 Hilton Atlanta, Atlanta, GA. Patient and Caregiver-reported symptoms and reasons for starting/stopping recombinant factor VIII treatment: Observations from the dosing observational study in hemophilia (DOSE). Abstract Code: PSY41.

Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.  Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C.Pediatr Hematol Oncol. 2011 Mar;28(2):167-72. doi: 10.3109/08880011003739414. Epub 2010 May 14

PubMed Search ID: Tugal O, and Levendoglu-Tugal, O.